Data show Zilver PTX leads to fewer complications and shorter hospital stays than traditional bypass surgery

497
Zilver PTX (Cook Medical)

At this year’s VEITHsymposium (19–23 November, New York, USA), Marc Bosiers presented data that show that patient treatment with the Zilver PTX stent has several benefits when compared to traditional bypass surgery. The data, which were gathered from a randomised controlled trial, show that treatment with Zilver PTX results in fewer complications and shorter hospital stays for patients with peripheral artery disease (PAD).1

To better understand the impact of Zilver PTX, Cook Medical funded a five-year physician-sponsored study called ZILVERPASS that compared the effects of treatment with Zilver PTX to traditional open prosthetic bypass surgery. The study was a randomised, multicentre trial that involved 220 patients in four countries.

The data presented at VEITHsymposium show that the procedure with Zilver PTX takes about half the time as a bypass procedure. Patients who were treated with Zilver PTX had a hospital stay that was on average five days shorter. Thirty days after the procedure, patients who were treated with Zilver PTX for long and complex lesions were 60% less likely to have complications than patients who had bypass surgery. In addition, other clinical outcomes of Zilver PTX were comparable to those of bypass surgery, according to the two-year data. This study is continuing to collect results through five years.

“Our mission with Zilver PTX—and with every product we make at Cook Medical—is to try to improve people’s lives. Cook Medical has released extensive data around Zilver PTX, and this device continues to show benefits across a wide spectrum of patients. We hope that by continuing the conversation around paclitaxel, physicians and patients can make more informed decisions,” said Mark Breedlove, vice president of Cook Medical’s Vascular division.

Marc Bosiers is a paid consultant for Cook Medical.

References 

  1. Bosiers M. 2-year results of the ZILVERPASS RCT comparing Zilver PTX DES treatment to open prosthetic bypasses for long femop lesions. Paper presented at: 46th Annual VEITHsymposium; November 19, 2019; New York City, NY.
  2. Song P, Rudan D, Zhu Y, et al. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health. 2019;7(8):e1020–e1030.

LEAVE A REPLY

Please enter your comment!
Please enter your name here